Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The study will investigate the effects of adding carfilzomib to the combination of
pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with
relapsed or refractory multiple myeloma. This portion of the study is complete.
This study will also investigate the effects of adding daratumumab to the combination of
carfilzomib, pomalidomide and dexamethasone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborators:
Multiple Myeloma Research Foundation National Cancer Institute (NCI)